跳至主要内容
临床试验/NCT00569777
NCT00569777已完成3 期

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers

Vistakon Pharmaceuticals3 个研究点 分布在 1 个国家目标入组 310 人开始时间: 2007年10月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
310
试验地点
3
主要终点
Lid and Lid Margin Erythema, Change From Baseline

研究概览

简要总结

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
8 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • healthy normal, soft contact lens wearing volunteers
  • normal ocular health
  • contact lens correction from +6.00 to -12.00D in each eye and astigmatism of -1.00D or less in each eye

排除标准

  • active ocular infection
  • history of ocular surgery
  • use of topical ophthalmic preparations (including rewetting drops)
  • pregnancy or lactation

结局指标

主要结局

Lid and Lid Margin Erythema, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Lid and Lid Margin Swelling, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Conjunctival Redness, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of redness of conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Conjunctival Chemosis, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Edema, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Erosion, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe.

Corneal Endothelial, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Lens Pathology, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Flare in Anterior Chamber, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Cells in Anterior Chamber, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Staining - Nasal, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes to the surface of cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Staining - Temporal, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes to the surface of the cornea, the region towards the outer edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Staining - Inferior, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Staining - Superior, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes to the surface of the cornea, upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Corneal Staining - Central, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes to the surface of the cornea, central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe.

Intraocular Pressure, Change From Baseline

时间窗: baseline and 12 weeks

Dilated Ophthalmoscopy - Fundus, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.

Dilated Ophthalmoscopy - Vitreous, Change From Baseline

时间窗: baseline and 12 weeks

Assessment of changes in the vitreous (gel-like fluid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.

Visual Acuity Assessment

时间窗: at 12 weeks

Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit.

次要结局

未报告次要终点

研究者

发起方
Vistakon Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

Safety Study of a Contact Lens With Ketotifen in... | 临床试验